Techcrunch
Longevity expert Dr. Peter Attia has stepped down as Chief Science Officer at David Protein, a high-protein nutrition bar company. This departure follows the release of documents linking Attia to Jeffrey Epstein, though the company and Attia's own startup have not commented.
AI 生成摘要
長壽專家彼得·阿提亞醫生已辭去高蛋白營養棒公司David Protein的首席科學官一職。此次離職發生在與愛潑斯坦有關的文件曝光之後，但公司及阿提亞自己的創辦公司均未對此置評。
Latest
AI
Amazon
Apps
Biotech & Health
Climate
Cloud Computing
Commerce
Crypto
Enterprise
EVs
Fintech
Fundraising
Gadgets
Gaming
Government & Policy
Hardware
Layoffs
Media & Entertainment
Meta
Microsoft
Privacy
Robotics
Security
Social
Space
Startups
TikTok
Transportation
Venture
Staff
Events
Startup Battlefield
StrictlyVC
Newsletters
Podcasts
Videos
Partner Content
TechCrunch Brand Studio
Crunchboard
Contact Us
The founder of David Protein, maker of popular high-protein nutrition bars, announced on X on Monday that longevity guru Dr. Peter Attia “has stepped down from his role as Chief Science Officer at David.”
The announcement comes after Attia’s name appeared in more than 1,700 documents, including email correspondence, released on Friday as part of a massive file dump related to convicted sex offender Jeffrey Epstein, according to The New York Times. Attia served on the executive team of the food startup and was also an early investor.
For those unfamiliar, Attia is a Canadian-American physician who has become one of the most prominent voices in longevity and preventive health. He’s best known for his bestselling book “Outlive: The Science and Art of Longevity” and his now seven-year-old podcast, wherein he explores optimization strategies. He was also hired just last month as a contributor to CBS.
Three-year-old, New York-based David Protein raised a $75 million Series A funding round in May of last year led by Greenoaks, with participation from Valor Equity Partners. The company has experienced significant growth since launching its flagship protein bar in September 2024, a product it describes has having 28 grams of protein, zero sugar, and 150 calories.
In a lengthy post on X, Attia wrote that he was “ashamed” of some of the crude content in his emails with Epstein, but he also said he was not involved in criminal activity and never visited Epstein’s island or traveled on his plane. Attia also discussed at length how he came to know Epstein and why he stayed involved with him even after Epstein’s 2008 conviction.
The fallout appears to extend beyond David Protein. It also appears that Biograph, the health care testing and longevity startup that Attia co-founded with entrepreneur John Hering, may be distancing itself from the physician. The company declined to comment on Attia’s ongoing participation with the startup or about the pages on its website that used to mention him but now omit his name or return a “file not found” error.
Biograph came out of stealth a year ago, TechCrunch previously reported, with backing from investors that include Vy Capital, Human Capital, Alpha Wave, and WndrCo, along with angel investors including Balaji Srinivasan. Like a growing number of concierge medical service companies, Biograph offers premium preventive health services to subscribers who pay between $7,500 to $15,000 per year. Attia was previously named on the company’s press release and site as a co-founder.
Topics
Venture Editor
Tickets are live at the lowest rates of the year. Save up to $680 on your pass now.Meet investors. Discover your next portfolio company. Hear from 250+ tech leaders, dive into 200+ sessions, and explore 300+ startups building what’s next. Don’t miss these one-time savings.
Fintech CEO and Forbes 30 Under 30 alum has been charged for alleged fraud
Meet the new European unicorns of 2026
Nvidia CEO pushes back against report that his company’s $100B OpenAI investment has stalled
OpenClaw’s AI assistants are now building their own social network
Elon Musk’s SpaceX, Tesla, and xAI in talks to merge, according to reports
Waymo robotaxi hits a child near an elementary school in Santa Monica
Tesla is killing off the Model S and Model X
© 2025 TechCrunch Media LLC.